Hong Kong Communications Stock News

SEHK:1211
SEHK:1211Auto

BYD Faces Brazil Dirty List Scrutiny And Valuation Questions For Investors

Brazilian authorities have added BYD Auto do Brasil to the country's "dirty list" of employers linked to exploitative working conditions at a Bahia plant construction project. The listing follows an investigation into labor practices at a contractor involved in building BYD's new manufacturing facility. BYD has ended its relationship with the contractor and issued public statements emphasizing its commitment to human rights. The company could now face tighter regulatory scrutiny,...
SEHK:753
SEHK:753Airlines

Air China Chengdu Brussels Route Tests Long Haul Demand And Profitability

Air China has launched a new direct passenger route between Chengdu and Brussels, creating a fresh air link between China and Belgium. The service is intended to support international connectivity and contribute to the recovery of inbound tourism in Chengdu. The new route forms part of Air China’s wider international network development and aligns with local infrastructure and travel facilitation efforts. For investors tracking Air China (SEHK:753), the new Chengdu to Brussels route lands...
SEHK:3933
SEHK:3933Pharmaceuticals

Assessing United Laboratories International Holdings (SEHK:3933) Valuation After Positive UBT251 Phase 2 Trial Results

Phase 2 data on UBT251 puts United Laboratories International Holdings in focus United Laboratories International Holdings (SEHK:3933) drew investor attention after releasing phase 2 data for UBT251 in China, showing HbA1c and body weight reductions against placebo and semaglutide in type 2 diabetes patients. The topline readout matters because it moves UBT251 closer to late stage development, supports the start of phase 3 trials in China, and ties directly into the company’s broader diabetes...
SEHK:2319
SEHK:2319Food

A Look At China Mengniu Dairy (SEHK:2319) Valuation After 2025 Earnings Recovery And Proposed Dividend

China Mengniu Dairy (SEHK:2319) has come into focus after releasing its full year 2025 results and proposing a final ordinary dividend of RMB 0.52 per share, subject to shareholder approval. See our latest analysis for China Mengniu Dairy. The latest earnings and dividend proposal appear to have supported sentiment, with a 30 day share price return of 6.36% and a 90 day share price return of 14.41% lifting the stock to HK$17.55. This comes even though the 1 year total shareholder return is a...
SEHK:326
SEHK:326Entertainment

A Look At China Star Entertainment (SEHK:326) Valuation After Weak 2025 Results And Widening Losses

China Star Entertainment (SEHK:326) just released full year 2025 results showing revenue of HK$404.92 million and a net loss of HK$443.76 million, broadly in line with guidance for a sizeable annual loss. See our latest analysis for China Star Entertainment. The weak 2025 results come after a sharp re-rating in the market, with the share price at HK$6.70 and a 30 day share price return of 45.34%. This has fed into a very large 1 year total shareholder return, suggesting momentum has been...
SEHK:2096
SEHK:2096Pharmaceuticals

Assessing Simcere Pharmaceutical Group (SEHK:2096) Valuation After Strong 2025 Earnings Report

Simcere Pharmaceutical Group (SEHK:2096) has drawn fresh attention after reporting full year 2025 sales of CN¥7,731.41 million and net income of CN¥1,344.01 million, alongside a proposed final dividend of CN¥0.18 per share. See our latest analysis for Simcere Pharmaceutical Group. At a latest share price of HK$13.62, Simcere Pharmaceutical Group has seen a 16.91% 1 month share price return and an 80.98% 1 year total shareholder return. Recent earnings, dividend and leadership announcements...
SEHK:3808
SEHK:3808Machinery

A Look At Sinotruk (Hong Kong) (SEHK:3808) Valuation After Strong 2025 Results And Higher Final Dividend Proposal

Sinotruk (Hong Kong) (SEHK:3808) has drawn fresh attention after reporting full year 2025 results with higher sales and net income, along with a board proposal to lift the ordinary final dividend for shareholders. See our latest analysis for Sinotruk (Hong Kong). The share price has responded strongly, with a 30 day share price return of 14.48% and a 90 day gain of 51.71%. The 1 year total shareholder return of 137.59% points to building momentum around the healthier earnings and higher...
SEHK:9969
SEHK:9969Biotechs

Assessing InnoCare Pharma (SEHK:9969) Valuation After Its 2025 Profit Turnaround

Earnings shift draws fresh attention to InnoCare Pharma InnoCare Pharma (SEHK:9969) has drawn fresh attention after reporting full year 2025 sales of CN¥2,374.91 million and net income of CN¥642.47 million, compared with a net loss a year earlier. See our latest analysis for InnoCare Pharma. The earnings swing has coincided with strong price momentum, with a 31.19% 1 month share price return and a 24.16% year to date share price return at HK$15.52. The 1 year total shareholder return of...
SEHK:656
SEHK:656Industrials

Assessing Fosun International (SEHK:656) Valuation After 2025 Loss And Shift In Dividend Policy

Fosun International (SEHK:656) has come under closer focus after reporting a larger net loss for 2025, withholding a dividend for the year, and outlining a higher dividend payout framework starting from the 2026 financial year. See our latest analysis for Fosun International. The recent dividend decision and larger 2025 net loss come after a mixed share price pattern, with a 19.5% 1 month share price return and a 9.91% 1 year total shareholder return contrasting with weaker multi year total...
SEHK:6855
SEHK:6855Biotechs

Assessing Ascentage Pharma Group International’s Valuation After Recent Share Price Momentum

Recent share performance and business snapshot Ascentage Pharma Group International (SEHK:6855) has drawn investor attention after recent share price moves, with returns of about 13% over the past week and 15% over the past month. The Suzhou based clinical stage biotech focuses on therapies for cancers, chronic hepatitis B and age related diseases in Mainland China. It generated HK$574.12 million in revenue and reported a net loss of HK$1,242.77 million. See our latest analysis for Ascentage...
SEHK:6699
SEHK:6699Medical Equipment

Assessing Angelalign Technology’s Valuation After Strong Earnings And Special Dividend Announcement

Why Angelalign Technology’s latest earnings and dividends matter for investors Angelalign Technology (SEHK:6699) has drawn fresh attention after releasing full year 2025 earnings, alongside a proposed special dividend of HK$4.99 per share and affirming its regular annual payout. See our latest analysis for Angelalign Technology. Since these results and dividend announcements, the share price has gained momentum, with a 30 day share price return of 11.71%, a year to date share price return of...